Natural products towards the discovery of potential future antithrombotic drugs

Current Pharmaceutical Design

Volumn 22, Issue 20, 2016, Pages 2926-2946

  Islam, Md Asiful ^a   Alam, Fahmida ^a   Khalil, Md Ibrahim ^a,b   Sasongko, Teguh Haryo ^a   Gan, Siew Hua ^a  

^a SCHOOL OF MEDICAL SCIENCES   (Malaysia)

^b JAHANGIRNAGAR UNIVERSITY   (Bangladesh)

Author keywords

Antithrombosis; Drug development; Drug interaction; Natural products

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; NATURAL PRODUCT; NIFEDIPINE; NUTRACEUTICAL; TICLOPIDINE; WARFARIN; BIOLOGICAL PRODUCT; FIBRINOLYTIC AGENT;

ANTICOAGULATION; ARTICLE; BLOOD CELL; CARDIOVASCULAR RISK; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; EDIBLE MUSHROOM; FIBRINOLYSIS; FRUIT; HEMOSTASIS; MEDICINAL PLANT; PRIORITY JOURNAL; SPICE; THROMBOCYTE AGGREGATION; THROMBOSIS; VEGETABLE; DRUG DEVELOPMENT; HUMAN;

BIOLOGICAL PRODUCTS; DRUG DISCOVERY; FIBRINOLYTIC AGENTS; HUMANS;

EID: 84973659244     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612822666160307150454     Document Type: Article

References (128)

1. Horton R. GBD 2010: understanding disease, injury, and risk. Lancet 2012; 380: 2053-4.
2. World Health Organization (WHO). Fact sheet: Cardiovascular diseases (CVDs). http://www.who.int/mediacentre/factsheets/ fs317/en/, March 2013.
3. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Nat Vital Stat Rep 2012; 61: 1-51.
4. Nikolaou K, Thieme S, Sommer W, Johnson T, Reiser MF. Diagnosing pulmonary embolism: new computed tomography applications. J Thoracic Imaging 2010; 25: 151-60.
5. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet 2012; 379: 1835-46.
6. Tapson VF. Acute pulmonary embolism. New Engl J Med 2008; 358: 1037-52.
7. P Dunn S, E Macaulay T. Drug-drug interactions associated with antiplatelet therapy. Cardiovasc Hematol Agents Med Chem 2011; 9: 231-40.
8. Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: A major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34: 2363-71.
9. Yeh GY, Davis RB, Phillips RS. Use of complementary therapies in patients with cardiovascular disease. Am J Cardiol 2006; 98: 673-80.
10. Stork M, Greene R. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy 2012; 27: 1237-47.
11. Aruna D, Naidu M. Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects. Br J Clin Pharmacol 2007; 63: 333-8.
12. Tsai H-H, Lin H-W, Lu Y-H, Chen Y-L, Mahady GB. A review of potential harmful interactions between anticoagulant/antiplatelet agents and Chinese herbal medicines. PloS One 2013; 8: 1-11.
13. Harvey AL, Edrada-Ebel R, Quinn RJ. The re-emergence of natural products for drug discovery in the genomics era. Nat Rev Drug Discov 2015.
14. Furie B, Furie BC. Mechanisms of thrombus formation. New Engl J Med 2008; 359: 938-49.
15. Konkle BA. Bleeding and thrombosis. New York: McGraw Hill 2008.
16. Key N, Makris M, O'Shaughnessy D, Lillicrap D. Practical hemostasis and thrombosis. USA: Wiley-Blackwell 2009.
17. Mackman N. Triggers, targets and treatments for thrombosis. Nature 2008; 451: 914-8.
18. Ruggeri ZM. Old concepts and new developments in the study of platelet aggregation. J Clin Invest 2000; 105: 699-701.
19. Bergmeier W, Piffath CL, Goerge T, et al. The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosis. Proc Natl Acad Sci USA 2006; 103: 16900-5.
20. Rumbaut RE, Thiagarajan P. Platelet-vessel wall interactions in hemostasis and thrombosis. San Rafael, California: Morgan & Claypool Life Sciences 2010.
21. Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 2008; 28: 403-12.
22. Riddel JP, Aouizerat BE, Miaskowski C, Lillicrap DP. Theories of blood coagulation. J Pediatr Oncol Nursing 2007; 24: 123-31.
23. Pallister C, Watson M. Haematology. UK: Scion Publishing 2010; pp. 336-47.
24. Schenone M, Furie BC, Furie B. The blood coagulation cascade. Curr Opin Hematol 2004; 11: 272-7.
25. Revel-Vilk S, Rand ML, Israels SJ. SickKids Handbook of Pediatric Thrombosis and Hemostasis. Basel, Switzerland: Karger Medical and Scientific Publishers 2013.
26. Dickson BC. Venous thrombosis: on the history of Virchow's triad. Univ Toronto Med J 2004; 81: 166-71.
27. Van De Graaff E, Steinhubl SR. Complications of oral antiplatelet medications. Curr Cardiol Rep 2001; 3: 371-9.
28. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. New Engl J Med 2011; 365: 2002-12.
29. World Health Organization. Legal status of traditional medicine and complementary/alternative medicine: a worldwide review. Geneva, Switzerland: World Health Organization 2001; pp. 1-189.
30. Franchini M, Mannucci PM. A new era for anticoagulants. Eur J Intern Med 2009; 20: 562-8.
31. Spyropoulos AC. Brave new world: The current and future use of novel anticoagulants. Thrombosis Res 2008; 123: 29-35.
32. Pawlaczyk I, Czerchawski L, Pilecki W, Lamer-Zarawska E, Gancarz R. Polyphenolic-polysaccharide compounds from selected medicinal plants of Asteraceae and Rosaceae families: Chemical characterization and blood anticoagulant activity. Carbohydr Polym 2009; 77: 568-75.
33. Shaw D, Leon C, Kolev S, Murray V. Traditional remedies and food supplements. A 5-year toxicological study (1991-1995). Drug Safety 1997; 17: 342-56.
34. De Smet PAGM, D'Arcy PF. Drug interactions with herbal and other non-toxic remedies. Berlin: Springer-Verlag 1996.
35. Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy: J Human Pharmacol Drug Ther 1999; 19: 870-6.
36. Izzat MB, Yim AP, El-Zufari MH. A taste of Chinese medicine! Ann Thoracic Surg 1998; 66: 941-2.
37. Yu CM, Chan JCN, Sanderson JE. Chinese herbs and warfarin potentiation by 'danshen'. J Intern Med 1997; 241: 337-9.
38. Jiang X, Williams KM, Liauw WS, et al. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2005; 59: 425-32.
39. Macan H, Uykimpang R, Alconcel M, et al. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr 2006; 136: 793-5.
40. Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50: 1933-3.
41. Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother 2000; 34: 1478-82.
42. Weidner MS, Sigwart K. The safety of a ginger extract in the rat. J Ethnopharmacol 2000; 73: 513-20.
43. Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin's effect in healthy patientsA randomized, controlled trial. Ann Intern Med 2004; 141: 23-7.
44. Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol 1999; 51: 175-80.
45. Jiang X, Williams KM, Liauw WS, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57: 592-9.
46. Wang Y, Zou MJ, Zhao N, Ren JG, Zhou H, Cheng G. Effect of diallyl trisulfide on the pharmacokinetics of nifedipine in rats. J Food Sci 2011; 76: 30-4.
47. Smith M, Lin K, Zheng YP. An open trial of nifedipine-herb interactions: Nufedipine with St. John's wort, Ginseng or Ginko biloba. Clin Pharmacol Ther 2001; 69: 86.
48. Ohnishi N, Kusuhara M, Yoshioka M, et al. Studies on interactions between functional foods or dietary supplements and medicines. I. Effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 2003; 26: 1315-20.
49. Rashid T, Martin U, Clarke H, Waller D, Renwick A, George C. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol 1995; 40: 51-8.
50. Young HY, Liao JC, Chang YS, Luo YL, Lu MC, Peng WH. Synergistic effect of ginger and nifedipine on human platelet aggregation: a study in hypertensive patients and normal volunteers. Am J Chinese Med 2006; 34: 545-51.
51. Apitz-Castro R, Escalante J, Vargas R, Jain MK. Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin and dypiridamole on human platelets. Thromb Res 1986; 42: 303-11.
52. Wang Y, Zou M, Zhao N, Ren J, Zhou H, Cheng G. Effect of diallyl trisulfide on the pharmacokinetics of dipyridamole in rats. Arch Pharm Res 2011; 34: 1957-64.
53. Kim YS, Pyo MK, Park KM, et al. Antiplatelet and Antithrombotic Effects of a Combination of Ticlopidine and Ginkgo biloba Ext (EGb 761). Thrombosis Res 1998; 91: 33-8.
54. Kim BH, Kim KP, Lim KS, et al. Influence of Ginkgo biloba extract on the pharmacodynamic effects and pharmacokinetic properties of ticlopidine: An open-label, randomized, two-period, twotreatment, two-sequence, single-dose crossover study in healthy Korean male volunteers. Clin Ther 2010; 32: 380-90.
55. Ryu KH, Han HY, Lee SY, et al. Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time. Thromb Res 2009; 124: 328-34.
56. Mateen AA, Rani PU, Naidu M, Chandrashekar E. Pharmacodynamic interaction study of Allium sativum (garlic) with cilostazol in patients with type II diabetes mellitus. Indian J Pharmacol 2011; 43: 270.
57. Capasso F, Gaginella TS, Grandolini G, Izzo AA. Phytotherapy: A quick reference to herbal medicine. USA: Springer 2003.
58. Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2005; 19: 1-16.
59. Gardner CD, Zehnder JL, Rigby AJ, Nicholus JR, Farquhar JW. Effect of Ginkgo biloba (EGb 761) and aspirin on platelet aggregation and platelet function analysis among older adults at risk of cardiovascular disease: a randomized clinical trial. Blood Coagul Fibrinol 2007; 18: 787-93.
60. Elmer GW, Lafferty WE, Tyree PT, Lind BK. Potential interactions between complementary/alternative products and conventional medicines in a Medicare population. Ann Pharmacother 2007; 41: 1617-24.
61. Chavez ML, Jordan MA, Chavez PI. Evidence-based drug-herbal interactions. Life Sci 2006; 78: 2146-57.
62. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci 2005; 78: 431-41.
63. Mendes-Silva W, Assafim M, Ruta B, Monteiro RQ, Guimarães JA, Zingali RB. Antithrombotic effect of glycyrrhizin, a plantderived thrombin inhibitor. Thrombosis Res 2003; 112: 93-8.
64. Merck & Co. Merck Statement on FDA Advisory Committee for Vorapaxar, Merck's Investigational Antiplatelet Medicine. New Jersey, USA: Merck & Co 2014.
65. Khoo LT, Abas F, Abdullah JO, Mohd Tohit ER, Hamid M. Anticoagulant Activity of Polyphenolic-Polysaccharides Isolated from Melastoma malabathricum L. Evid-Based Complement Alternat Med 2014; 2014: 1-8.
66. Manukumar H, Shruthi K. Screening of thrombolytic (Clot- Busting) activity from geographically separated two varieties of honey from india: an in-vitro approach. World J Pharm Pharm Sci 2014; 3: 1428-39.
67. Zhou W, Abdurahman A, Umar A, et al. Effects of Cydonia oblonga Miller extracts on blood hemostasis, coagulation and fibrinolysis in mice, and experimental thrombosis in rats. J Ethnopharmacol 2014; 154: 163-9.
68. Choi JH, Kim DW, Park SE, et al. Novel thrombolytic protease from edible and medicinal plant Aster yomena (Kitam.) Honda with anticoagulant activity: Purification and partial characterization. J Biosci Bioeng 2014; 118: 372-7.
69. Hossen S, Sarkar MMI, Jahid MA. Assessment of thrombolytic activity of five bangladeshi medicinal plants: potential source for thrombolytic compounds. Intern Blood Res Rev 2014; 2: 262-9.
70. Ali M, Hossain M, Runa JF, Hasanuzzaman M, Islam M. Evaluation of thrombolytic potential of three medicinal plants available in Bangladesh, as a potent source of thrombolytic compounds. Avicenna J Phytomed 2014: 1-7 (Article in press).
71. Rahman MA, Sultana R, Emran TB, et al. Effects of organic extracts of six Bangladeshi plants on in vitro thrombolysis and cytotoxicity. BMC Complement Alternat Med 2013; 13: 25.
72. Dewan SMR, Das A. Investigation of in vitro thrombolytic potential and phytochemical nature of Crinum latifolium L. leaves growing in coastal region of Bangladesh. Int J Biol Pharm Res 2013; 4: 1-7.
73. Arslan R, Bor Z, Bektas N, Meriçli AH, Ozturk Y. Antithrombotic effects of ethanol extract of Crataegus orientalis in the carrageenan- induced mice tail thrombosis model. Thromb Res 2011; 127: 210-3.
74. Prakash P, Misra A, Surin WR, et al. Anti-platelet effects of Curcuma oil in experimental models of myocardial ischemiareperfusion and thrombosis. Thromb Res 2011; 127: 111-8.
75. Malik N, Dhawan V, Bahl A, Kaul D. Inhibitory effects of Terminalia arjuna on platelet activation in vitro in healthy subjects and patients with coronary artery disease. Platelets 2009; 20: 183-90.
76. Jain M, Yadav A, Tomar V, Kannojia P, Solanki SS, Tonpay SD. Possible pharmacological basis for antithrombotic effect of glycyrrhiza glabra in sprague dawley rats. Int J Pharm Sci Drug Res 2009; 1: 113-5.
77. Kee NLA, Mnonopi N, Davids H, Naudé RJ, Frost CL. Antithrombotic/ anticoagulant and anticancer activities of selected medicinal plants from South Africa. Afr J Biotechnol 2008; 7.
78. Yazdanparast R, Shahriyary L. Comparative effects of Artemisia dracunculus, Satureja hortensis and Origanum majorana on inhibition of blood platelet adhesion, aggregation and secretion. Vasc Pharmacol 2008; 48: 32-7.
79. Prasad S, Kashyap RS, Deopujari JY, Purohit HJ, Taori GM, Daginawala HF. Effect of Fagonia Arabica (Dhamasa) on in vitro thrombolysis. BMC Complement Alternat Med 2007; 7: 36.
80. Satake T, Kamiya K, An Y, Oishi T, Yamamoto J. The antithrombotic active constituents from Centella asiatica. Biol Pharm Bull 2007; 30: 935-40.
81. Tognolini M, Ballabeni V, Bertoni S, Bruni R, Impicciatore M, Barocelli E. Protective effect of Foeniculum vulgare essential oil and anethole in an experimental model of thrombosis. Pharmacol Res 2007; 56: 254-60.
82. Jin YR, Yu JY, Lee JJ, et al. Antithrombotic and antiplatelet activities of Korean red ginseng extract. Basic Clin Pharmacol Toxicol 2007; 100: 170-5.
83. Tohti I, Tursun M, Umar A, Turdi S, Imin H, Moore N. Aqueous extracts of Ocimum basilicum L.(sweet basil) decrease platelet aggregation induced by ADP and thrombin in vitro and rats arterio- venous shunt thrombosis in vivo. Thromb Res 2006; 118: 733-9.
84. Jantan I, Rafi I, Jalil J. Platelet-activating factor (PAF) receptorbinding antagonist activity of Malaysian medicinal plants. Phytomedicine 2005; 12: 88-92.
85. Yamamoto J, Yamada K, Naemura A, Yamashita T, Arai R. Testing various herbs for antithrombotic effect. Nutrition 2005; 21: 580-7.
86. Mekhfi H, Haouari ME, Legssyer A, et al. Platelet anti-aggregant property of some Moroccan medicinal plants. J Ethnopharmacol 2004; 94: 317-22.
87. Son DJ, Cho M-R, Jin Y-R, et al. Antiplatelet effect of green tea catechins: a possible mechanism through arachidonic acid pathway. Prostaglandins, Leukot Essent Fatty Acids 2004; 71: 25-31.
88. 2+ mobilization in activated human platelets. Life Sci 2004; 75: 3063-76.
89. Yoon SJ, Pereira MS, Pavão MS, Hwang J-K, Pyun Y-R, Mourão PA. The medicinal plant Porana volubilis contains polysaccharides with anticoagulant activity mediated by heparin cofactor II. Thromb Res 2002; 106: 51-8.
90. Parvin D, Uddin M, Islam M, Parvin S, Shahriar M. Phytochemical screenings, thrombolytic activity and antimicrobial properties of the leaf extracts of Lablab parpureus. Am J Res Commun 2013; 1: 49-55.
91. Fuentes EJ, Astudillo LA, Gutiérrez MI, et al. Fractions of aqueous and methanolic extracts from tomato (Solanum lycopersicum L.) present platelet antiaggregant activity. Blood Coagul Fibrinol 2012; 23: 109-17.
92. Sabha D, Hiyasat B, Grötzinger K, et al. Allium ursinum L.: bioassay- guided isolation and identification of a galactolipid and a phytosterol exerting antiaggregatory effects. Pharmacology 2012; 89: 260-9.
93. Junichiro Y, Megumi M, Kanae H, Masahiro I. Experimental antithrombotic effect of potatoes harvested in the autumn. Health 2012; 4: 108-12.
94. Torres-Urrutia C, Guzman L, Schmeda-Hirschmann G, et al. Antiplatelet, anticoagulant, and fibrinolytic activity in vitro of extracts from selected fruits and vegetables. Blood Coagul Fibrinol 2011; 22: 197-205.
95. Hyodo K, Horii I, Nishino M, Giddings JC, Yamamoto J. The antithrombotic effects of onion filtrates in rats and mice. Health 2011; 3: 319-25.
96. IM TE, Izzalddeen MMAHM, Abdalkareem MA, Abdalraheem MA, Alhassan MB. Evidence for an in vitro anticoagulant activity of red onion (Allium cepa L.). Sudan J Med Sci 2011; 6: 85-8.
97. Bungu L, van de Venter M, Frost C. Evidence for an in vitro anticoagulant and antithrombotic activity in Tulbaghia violacea. African J Biotechnol 2008; 7: 681-8.
98. Yamamoto J, Naemura A, Ijiri Y, et al. The antithrombotic effects of carrot filtrates in rats and mice. Blood Coagul Fibrinol 2008; 19: 785-92.
99. Manik MK, Islam SM, Wahid MA, et al. Investigation of in vitro antioxidant, antimicrobial and thrombolytic activity of the exocarp of Spondias pinnata (Anacardiaceae). Canadian Chem Transact 2013; 1: 191-201.
100. Klafke JZ, Arnoldi da Silva M, Fortes Rossato M, et al. Antiplatelet, antithrombotic, and fibrinolytic activities of Campomanesia xanthocarpa. Evid-Based Complement Alternat Med 2011; 2012: 1-8.
101. Ansari AV, Siddiqui HH, Singh SP. Antithrombotic and Thrombolytic activity of Terminalia belerica fruit extracts. Res J Pharm Biol Chem Sci 2012; 471-8.
102. Xin N, Li YJ, Li Y, et al. Dragon's Blood extract has antithrombotic properties, affecting platelet aggregation functions and anticoagulation activities. J Ethnopharmacol 2011; 135: 510-4.
103. Gläser D, Hilberg T. The influence of bromelain on platelet count and platelet activity in vitro. Platelets 2006; 17: 37-41.
104. Yamamoto J, Naemura A, Ura M, et al. Testing various fruits for anti-thrombotic effect: I. Mulberries. Platelets 2006; 17: 555-64.
105. Naemura A, Mitani T, Ijiri Y, et al. Anti-thrombotic effect of strawberries. Blood Coagul Fibrinol 2005; 16: 501-9.
106. Jung KA, Song T-C, Han D, Kim I-H, Kim Y-E, Lee C-H. Cardiovascular protective properties of kiwifruit extracts in vitro. Biol Pharm Bull 2005; 28: 1782-5.
107. Duttaroy AK, Jørgensen A. Effects of kiwi fruit consumption on platelet aggregation and plasma lipids in healthy human volunteers. Platelets 2004; 15: 287-92.
108. Keevil JG, Osman HE, Reed JD, Folts JD. Grape juice, but not orange juice or grapefruit juice, inhibits human platelet aggregation. J Nutr 2000; 130: 53-6.
109. Asif F, Boby AZ, Alam N, Taraquzzaman M, Chowdhury SR, Rashid MA. Canvassing of thrombolytic, cytotoxic, and erythrocyte membrane-stabilizing attributes in in vitro screening of Gynocardia odorata. J Anal Sci Technol 2014; 5: 1-7.
110. Rahman M, Khatun A, Islam M, et al. Evaluation of antimicrobial, cytotoxic, thrombolytic, diuretic properties and total phenolic content of Cinnamomum tamala. Int J Green Pharm 2013; 7: 236-43.
111. Swamy PL, Prasad V, Govind V, Rao TS, Kumar LCA, Rao G. Invitro investigation on fibrinolytic activity of selected indigenous plants and culinary spices. Inventi Impact: Ethnopharmacology 2013.
112. Lee H. Antiplatelet property of Curcuma longa L. rhizome-derived ar-turmerone. Biores Technol 2006; 97: 1372-6.
113. Nurtjahja-Tjendraputra E, Ammit AJ, Roufogalis BD, Tran VH, Duke CC. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res 2003; 111: 259- 65.
114. Shirasaka N, Naitou M, Okamura K, Fukuta Y, Terashita T, Kusuda M. Purification and characterization of a fibrinolytic protease from Aspergillus oryzae KSK-3. Mycoscience 2012; 53: 354-64.
115. Rashad MM, Mahmoud AE, Al-Kashef AS, Nooman MU. Purification and characterization of a novel fibrinolytic enzyme by Candida guilliermondii Grown on Sunflower Oil Cake. J Appl Sci Res 2012; 8: 635-45.
116. Telles C, Sabry DA, Almeida-Lima J, et al. Sulfation of the extracellular polysaccharide produced by the edible mushroom Pleurotus sajor-caju alters its antioxidant, anticoagulant and antiproliferative properties in vitro. Carbohydr Polym 2011; 85: 514-21.
117. Chang Z, Hwang M, Rhee M, et al. The in vitro anti-platelet, antioxidant and cellular immunity activity of Phellinus gilvus fractional extracts. World J Microbiol Biotechnol 2008; 24: 181-7.
118. Ueda M, Kubo T, Miyatake K, Nakamura T. Purification and characterization of fibrinolytic alkaline protease from Fusarium sp. BLB. Appl Microbiol Biotechnol 2007; 74: 331-8.
119. Hyun KW, Jeong SC, Lee DH, Park JS, Lee JS. Isolation and characterization of a novel platelet aggregation inhibitory peptide from the medicinal mushroom, Inonotus obliquus. Peptides 2006; 27: 1173-8.
120. Yoon SJ, Yu M, Pyun Y-R, et al. The nontoxic mushroom Auricularia auricula contains a polysaccharide with anticoagulant activity mediated by antithrombin. Thromb Res 2003; 112: 151-8.
121. Apitz-Castro R, Badimon JJ, Badimon L. Effect of ajoene, the major antiplatelet compound from garlic, on platelet thrombus formation. Thromb Res 1992; 68: 145-55.
122. Teng CM, Li HL, Wu TS, Huang SC, Huang TF. Antiplatelet actions of some coumarin compounds isolated from plant sources. Thromb Res 1992; 66: 549-57.
123. Chen IS, Chang CT, Sheen WS, et al. Coumarins and antiplatelet aggregation constituents from formosan Peucedanum japonicum. Phytochemistry 1996; 41: 525-30.
124. Orsini F, Pelizzoni F, Verotta L, Aburjai T, Rogers CB. Isolation, synthesis, and antiplatelet aggregation activity of resveratrol 3-O-β-D-glucopyranoside and related compounds. J Nat Prod 1997; 60: 1082-7.
125. Demrow HS, Slane PR, Folts JD. Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 1995; 91: 1182-8.
126. Nurtjahja Tjendraputra E, Ammit AJ, Roufogalis BD, Tran VH, Duke CC. Effective anti-platelet and COX-1 enzyme inhibitors from pungent constituents of ginger. Thromb Res 2003; 111: 259- 65.
127. Mendes Silva W, Assafim M, Ruta B, Monteiro RQ, Guimarães JA, Zingali RB. Antithrombotic effect of glycyrrhizin, a plantderived thrombin inhibitor. Thromb Res 2003; 112: 93-8.
128. Pawlaczyk I, Czerchawski L, Kuliczkowski W, et al. Anticoagulant and anti-platelet activity of polyphenolic-polysaccharide preparation isolated from the medicinal plant Erigeron canadensis L. Thromb Res 2011; 127: 328-40.